Traws Pharma Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Public

  • Employees
  • 7

Employees

  • Stock Symbol
  • TRAW

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.24
  • (As of Wednesday Closing)

Traws Pharma General Information

Description

Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.

Contact Information

Formerly Known As
Onconova Therapeutics, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • 12 Penns Trail
  • Newtown, PA 18940
  • United States
+1 (267)
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Stock Exchange
NAS
Corporate Office
  • 12 Penns Trail
  • Newtown, PA 18940
  • United States
+1 (267)

Traws Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Traws Pharma Stock Performance

As of 18-Nov-2026, Traws Pharma’s stock price is $0.24. Its current market cap is $3.73M with 15.4M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.24 $0.23 $0.22 - $3.23 $3.73M 15.4M 610K -$1.71

Traws Pharma Financials Summary

As of 30-Jun-2026, Traws Pharma has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 9,644 2,610 21,457 (9,584)
Revenue 0 2,790 226 226
EBITDA (21,419) 9,231 (166,511) (18,932)
Net Income (21,566) 9,170 (166,523) (18,948)
Total Assets 11,470 10,617 24,962 22,683
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Traws Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Traws Pharma‘s full profile, request access.

Request a free trial

Traws Pharma Patents

Traws Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026122604-A1 Synthesis of (1r,2s,5s)-n-[(1s)-1-cyano-2-(2-oxoindolin-3-yl)ethyl]-3-[(2s)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide Pending 02-Dec-2024
JP-2025520539-A Compounds for the treatment of coronavirus infections Pending 17-Jun-2022
JP-2025520541-A Compounds for the treatment of coronavirus infections Pending 17-Jun-2022
AU-2023293272-A1 Compounds for treatment a coronavirus infection Active 17-Jun-2022
AU-2023293272-B2 Compounds for treatment a coronavirus infection Active 17-Jun-2022 C07K5/06034
To view Traws Pharma’s complete patent history, request access »

Traws Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Traws Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Traws Pharma‘s full profile, request access.

Request a free trial

Traws Pharma Acquisitions (1)

Traws Pharma’s most recent deal was a Merger/Acquisition with Onconova Therapeutics. The deal was made on 01-Apr-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Onconova Therapeutics 01-Apr-2024 Merger/Acquisition Biotechnology
To view Traws Pharma’s complete acquisitions history, request access »

Traws Pharma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

41.97 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Traws Pharma’s complete esg history, request access »

Traws Pharma FAQs

  • When was Traws Pharma founded?

    Traws Pharma was founded in 2021.

  • Where is Traws Pharma headquartered?

    Traws Pharma is headquartered in Newtown, PA.

  • What is the size of Traws Pharma?

    Traws Pharma has 7 total employees.

  • What industry is Traws Pharma in?

    Traws Pharma’s primary industry is Drug Discovery.

  • Is Traws Pharma a private or public company?

    Traws Pharma is a Public company.

  • What is Traws Pharma’s stock symbol?

    The ticker symbol for Traws Pharma is TRAW.

  • What is the current stock price of Traws Pharma?

    As of 18-Nov-2026 the stock price of Traws Pharma is $0.24.

  • What is the current market cap of Traws Pharma?

    The current market capitalization of Traws Pharma is $3.73M.

  • What is Traws Pharma’s annual earnings per share (EPS)?

    Traws Pharma’s EPS for 12 months was -$1.71.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process